Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

Regeneron tops best science employer poll again

October 17, 2014
Life sciences
Regeneron has once again come top of Science magazine’s top 20 employers survey, followed by Novo Nordisk and Roche’s Genentech unit.
 
The poll is based on 5,394 responses from readers of Science and employees in the biotechnology and pharmaceutical industry, who were asked to rank the best employers on a number of characteristics. The categories included ‘’innovative leader in the industry’, treats employees with respect’, ‘has loyal employees’ and ‘is socially responsible’.
 
Regeneron came out as the top company for the third year in a row, while Novo leapt to second from 11th place last year. They were followed by Genentech, Vertex (4), Eli Lilly (5), AbbVie (7) and Roche itself, up eight places from last year to eighth.
 
Biogen Idec came in at 10th, while Novartis slipped three places to 11th. Newcomers to the list were Actelion (14), Johnson & Johnson (19) and Merck KGaA (20). The other pharma players in the top 20 are Boehringer Ingelheim (13, down from 9), Celgene (up two places to 15), Bayer (up four to 16) and Amgen, which rose one place to 18th.
 
Science claims that “a common thread runs through the top 20 list: give employees the intellectual freedom and support necessary to pursue high-risk/high-reward goals – and they’ll deliver”. The journal says that by adding “a noble mission” to this, “employers can create a positive feedback loop that maximises employees’ drive and dedication as well as company profits”.
 
By Kevin Grogan
 

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

Read more
April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

Read more
April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

Read more
More news

How can we help you?

We're easy to reach